5. References

  1. IBM Micromedex® DRUGDEX® (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at: https://www-micromedexsolutions-com.libproxy.uthscsa.edu/ (cited: June 8, 2021).
  2. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2021. Available at: http://clinicalpharmacology-ip.com.ezproxy.lib.utexas.edu/. Accessed June 8, 2021.
  3. Facts and Comparisons eAnswers [database online]. Hudson, Ohio: Wolters Kluwer Clinical Drug Information, Inc.; 2021; June 8, 2021.
  4. AHFS Drug Information 2021. Jackson, WY: Teton Data Systems. Stat!Ref Electronic Medical Library. Available at: http://online-statref-com.libproxy.uthscsa.edu/. Accessed June 8, 2021. 
  5. Rivastigmine transdermal system (Exelon® Patch) package insert.  Novartis, December 2020.
  6. Galantamine extended-release capsules, tablets and oral solution (Razadyne® ER, Razadyne®) package insert. Janssen Pharmaceuticals, September 2020.
  7. Donepezil tablets, orally disintegrating tablets (Aricept®, Aricept® ODT) Package Insert. Eisai Inc., December 2018.
  8. Memantine extended-release/donepezil capsules (Namzaric®) package insert. Allergan USA, Inc., January 2019.
  9. Farlow MR, Cummings JL.  Effective pharmacologic management of Alzheimer’s disease. Am J Med. 2007;120:388-97.
  10. Blennow K, deLeon MJ, Zetterberg H. Alzheimer’s disease. Lancet. 2006;368:387-403.
  11. Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006, Issue 1. Art. No.: CD005593. DOI: 10.1002/14651858.CD005593.
  12. Press D, Alexander M. Cholinesterase inhibitors in the treatment of dementia. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. (Accessed on June 8, 2021.)
  13. Mayeux R. Clinical practice. Early Alzheimer's disease. N Engl J Med.  2010;362(23):2194-201.
  14. Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med. 2008;148(5):379-97.
  15. Deardorff WJ, Grossberg GT. A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer's disease. Drug Des Devel Ther. 2016;10:3267-79.
  16. Szeto JY, Lewis SJ. Current treatment options for Alzheimer's disease and Parkinson's disease dementia. Curr Neuropharmacol. 2016;14(4):326-38.
  17. Ehret MJ, Chamberlin KW. Current practices in the treatment of Alzheimer disease: where is the evidence after the phase III trials? Clin Ther. 2015;37(8):1604-16.
  18. Kumar A, Singh A, Ekavali. A review on Alzheimer’s disease pathophysiology and its management: an update. Pharmacol Rep. 2015;67(2):195-203.
  19. Howard E, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer’s disease. N Engl J Med. 2012;366(10):893-903.
  20. Epperly T, Dunay MA, Boice JL.  Alzheimer disease: pharmacologic and nonpharmacologic therapies for cognitive and functional symptoms. Am Fam Physician. 2017;95(12):771-8. 
  21. Grossberg GT, Tong G, Burke AD, Tariot PN. Present Algorithms and Future Treatments for Alzheimer's Disease. J Alzheimers Dis. 2019;67(4):1157-1171.